2023 - Research.com Medicine in Netherlands Leader Award
Jan H.M. Schellens mostly deals with Pharmacology, Pharmacokinetics, Internal medicine, Drug and Oncology. His Pharmacology research includes themes of Paclitaxel, Toxicity and Docetaxel. He interconnects Area under the curve, Adverse effect, Chemotherapy and Dosing in the investigation of issues within Pharmacokinetics.
His Internal medicine research is multidisciplinary, incorporating perspectives in Gastroenterology, Endocrinology and DPYD. His biological study deals with issues like ATP-binding cassette transporter, which deal with fields such as P-glycoprotein. In his study, which falls under the umbrella issue of Oncology, Colorectal cancer and Cetuximab is strongly linked to Clinical trial.
His primary scientific interests are in Pharmacology, Pharmacokinetics, Internal medicine, Chromatography and Oncology. His Pharmacology study combines topics from a wide range of disciplines, such as Paclitaxel and Toxicity. His Pharmacokinetics study incorporates themes from Tolerability, Adverse effect, Neutropenia and Dosing.
His study brings together the fields of Gastroenterology and Internal medicine. His study focuses on the intersection of Oncology and fields such as Capecitabine with connections in the field of DPYD. His research investigates the link between Tandem mass spectrometry and topics such as Metabolite that cross with problems in Urine.
His primary areas of investigation include Internal medicine, Oncology, Pharmacokinetics, Pharmacology and Cancer. His Internal medicine research is multidisciplinary, relying on both Gastroenterology and DPYD. The Oncology study combines topics in areas such as Colorectal cancer, Clinical trial, Trametinib and Prospective cohort study.
His Pharmacokinetics research incorporates themes from Tolerability, Pazopanib and Chromatography. His research in Pharmacology intersects with topics in Intracellular, Tyrosine-kinase inhibitor and Cutaneous leishmaniasis. His Cancer study integrates concerns from other disciplines, such as Lung cancer and Pathology.
Jan H.M. Schellens mainly focuses on Internal medicine, Oncology, Pharmacology, Cancer and Pharmacokinetics. In his work, Vomiting, Oral administration and Anesthesia is strongly intertwined with Gastroenterology, which is a subfield of Internal medicine. Jan H.M. Schellens combines subjects such as Clinical trial, Capecitabine, Dihydropyrimidine dehydrogenase and DPYD with his study of Oncology.
His Pharmacology research is multidisciplinary, incorporating elements of Miltefosine, Chemotherapy and Toxicity. His Cancer study combines topics in areas such as Lung cancer, Drug approval and MEDLINE. Jan H.M. Schellens has included themes like Tyrosine-kinase inhibitor, Pazopanib and Drug in his Pharmacokinetics study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Peter C Fong;David S Boss;Timothy A Yap;Andrew Tutt.
The New England Journal of Medicine (2009)
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
M Maliepaard;G L Scheffer;I F Faneyte;M A van Gastelen.
Cancer Research (2001)
A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
Jeany M. Rademaker-Lakhai;Desiree van den Bongard;Dick Pluim;Jos H. Beijnen.
Clinical Cancer Research (2004)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong;Timothy A. Yap;David S. Boss;Craig P. Carden.
Journal of Clinical Oncology (2010)
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
John D Allen;Arnold van Loevezijn;Jeany M Lakhai;Martin van der Valk.
Molecular Cancer Therapeutics (2002)
Photodynamic Therapy in Oncology
Martijn Triesscheijn;Paul Baas;Jan H. M. Schellens;Jan H. M. Schellens;Fiona A. Stewart.
Role of Breast Cancer Resistance Protein in the Bioavailability and Fetal Penetration of Topotecan
Johan W. Jonker;Johan W. Smit;Remco F. Brinkhuis;Marc Maliepaard.
Journal of the National Cancer Institute (2000)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz;Axel Grothey;Rona Yaeger;Eric Van Cutsem.
The New England Journal of Medicine (2019)
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.
Esther F.A Brandon;Christiaan D Raap;Irma Meijerman;Jos H Beijnen;Jos H Beijnen.
Toxicology and Applied Pharmacology (2003)
Overexpression of the BCRP/MXR/ABCP Gene in a Topotecan-selected Ovarian Tumor Cell Line
Maliepaard M;van Gastelen Ma;de Jong La;Pluim D.
Cancer Research (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: